These preliminary data suggest that a chronic treatment with PEA or a single administration with mGluR5 blockers (or a combination of both) affect discriminative memory and LTP at the LEC-DG pathway in neuropathic pain conditions, in which a decline of LTP and discriminative memory was observed. This evidence concerns the gene GRM5 and neuropathic pain.